title: Synthesis of some oxime ether derivatives of 1-(2-naphthyl)-2-(1,2,4-triazol-1-yl)ethanone and their anticonvulsant and antimicrobial activities.
abstract: In this study, oxime and oxime ether derivatives of [1-(2-naphthyl)-2-(1,2,4-triazol-1-yl)ethanone] were prepared as potential anticonvulsant and antimicrobial compounds. The oxime was synthesized by the reaction of ketone and hydroxylamine hydrochloride. O-Alkylation of the oxime by various alkyl halides gave the oxime ether derivatives. Anticonvulsant activity of the compounds was determined by maximal electroshock and subcutaneous metrazole tests in mice and rats according to procedures of the Anticonvulsant Screening Program of National Institutes of Health. Neurotoxicity was determined by the rotorod test in mice and the positional sense test, gait and stance test in rats. In addition to anticonvulsant tests, all compounds were also evaluated against the following microorganisms: S. aureus, E. coli, P. aeruginosa, E. faecalis, C. albicans, C. parapsilosis, and C. krusei using microdilution broth method for possible antibacterial and antifungal activities. Although most of the O-alkyl substituted oxime ethers exhibited both anticonvulsant and antimicrobial activities, the O-arylalkyl substituted compounds were found to be inactive in both screening paradigms.
authors.affiliation: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
authors.forename: Arzu
authors.initials: A
authors.lastname: Karakurt
authors.forename: Mutlu D
authors.initials: MD
authors.lastname: Aytemir
authors.forename: James P
authors.initials: JP
authors.lastname: Stables
authors.forename: Meral
authors.initials: M
authors.lastname: Ozalp
authors.forename: F
authors.initials: F
authors.lastname: Betül Kaynak
authors.forename: Süheyla
authors.initials: S
authors.lastname: Ozbey
authors.forename: Sevim
authors.initials: S
authors.lastname: Dalkara
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000138:chemical synthesis / Q000494:pharmacology*; D000927:Anticonvulsants / Q000138:chemical synthesis / Q000494:pharmacology*; D000935:Antifungal Agents / Q000138:chemical synthesis / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects / Q000254:growth & development; D018360:Crystallography, X-Ray; D004353:Drug Evaluation, Preclinical / Q000379:methods; D007274:Injections, Intraperitoneal; D051379:Mice; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D009281:Naphthalenes / Q000138:chemical synthesis / Q000494:pharmacology*; D010091:Oximes / Q000138:chemical synthesis / Q000494:pharmacology*; D051381:Rats; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D014230:Triazoles / Q000138:chemical synthesis / Q000494:pharmacology*
chemical_list: C514967:1-(2-naphthyl)-2-(1,2,4-triazol-1-yl)ethanone; D000900:Anti-Bacterial Agents; D000927:Anticonvulsants; D000935:Antifungal Agents; D009281:Naphthalenes; D010091:Oximes; D014230:Triazoles